Compared to matched controls, patients on metformin monotherapy did not show significant excess mortality during follow-up, but patients on sulfonylurea or insulin monotherapy had higher mortality rates.
The population-based prospective cohort analysis of adults who were members of a single U.S. health care delivery system compared CHD risk among those with and without a history of diabetes or CHD.
A “virtual clinic” model involving consultations between diabetes subspecialists and primary care physicians was associated with glycemic improvements in treated patients and controls from the same practices, a British study found.
The authors stated that the impact of prediabetes awareness on the odds of adopting risk-reducing lifestyle factors highlights the special influence of physician input on patient behavior.
Once-weekly glucagon-like peptide 1 (GLP-1) receptor agonists lower HbA1c without increasing body weight, a review found.
Patients who were under age 55 faced a more substantial increase in mortality risk from having diabetes than older patients.
DPP-4 inhibitors associated with lower mortality and cardiac risk than sulfonylureas as add-on therapy, study finds
When added to metformin, DPP-4 inhibitors were associated with reduced risks for all-cause death and stroke but did not appear to alter the risks for myocardial infarction and hospitalization for heart failure relative to sulfonylureas.
More patients would be eligible for metformin use if estimated glomerular filtration rate were used to define kidney disease rather than serum creatinine, a recent study concluded.
The estimated prevalence of diabetes among U.S. adults ranged between 12% and 14% in 2011-2012, according to a recent study.
Pioglitazone was not found to be associated with a statistically significant increased risk of bladder cancer or 8 of 10 additional cancers in a recent study.